Alle Storys
Folgen
Keine Story von Merck Healthcare Germany GmbH mehr verpassen.

Merck Healthcare Germany GmbH

Merck Launches Online Platform Fertility.com

Germany (ots/PRNewswire)

Not intended for U.S. based media

- Fertility.com is the gateway to two online portals: 
- Offering the latest scientific information to healthcare 
  professionals in the advancing field of fertility 
- Supporting women, men and couples who are looking for information 
  about fertility and/or undergoing fertility treatment

(Photo: https://mma.prnewswire.com/media/713837/Merck_Fertility_com.jpg )

(Photo: https://mma.prnewswire.com/media/713838/Fertility_com.jpg )

Merck, a leading science and technology company, today announces the launch of the new online portal fertility.com. Fertility.com is the entrance to access two unique and bespoke portals:

- Fertility.com/hcp; developed for fertility Healthcare Professionals
  (HCPs)
- Fertility.com/support; created for women, men and couples who are 
  looking for information about fertility and/or are undergoing 
  fertility treatment

The Healthcare Professional Portal (fertility.com/hcp) offers a wide range of resources relevant to physicians' daily practice. On the portal, healthcare professionals can find key medical and scientific content. This includes the latest news, publications and developments in the field of fertility as well as expert opinion videos and educational materials. The portal also provides the opportunity to discover more about Merck's therapeutics, technologies and services.

The Patient Support Portal (fertility.com/support) has been created to provide a profound source of information for women, men and couples who are trying or have been trying to conceive. The portal is designed to support patients at every step of their fertility journey, including educational materials that help them understand fertility and treatment options. They can also find lifestyle advice to improve their chances for success.

Fertility.com is designed with convenience and easy navigation in mind, ensuring that patients and physicians can easily access the information they need, anytime and everywhere. This new online platform demonstrates Merck's commitment to continuing to support people trying to conceive, whilst also offering HCPs a scientific platform with the latest advances in reproductive medicine.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of EUR 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

(Logo: http://mma.prnewswire.com/media/472778/Merck_Logo.jpg )

Your Contact: Dr. Raphaela Farrenkopf, +49-6151-72-2274

Weitere Storys: Merck Healthcare Germany GmbH
Weitere Storys: Merck Healthcare Germany GmbH
  • 02.07.2018 – 13:16

    Merck Launches Two New Technologies for Improved Efficiency in Fertility Labs

    Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - QBOX IVF streamlines data transfer between lab instruments and Electronic Medical Record providers - Geri® Assess 2.0 enables automatic detection of key events in embryo and blastocyst development, improving efficiencies in assessment - Merck demonstrates commitment to further advance and ...

  • 04.06.2018 – 14:16

    Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

    Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an investigational immunotherapy that is designed to bring together ...